Evrard, C.; Aparicio, T.; Soularue, E.; Le Malicot, K.; Desramé, J.; Botsen, D.; El Hajbi, F.; Gonzalez, D.; Lepage, C.; Bouché, O.;
et al. Safety of FOLFIRI + Durvalumab +/− Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59. Biomedicines 2022, 10, 1211.
https://doi.org/10.3390/biomedicines10051211
AMA Style
Evrard C, Aparicio T, Soularue E, Le Malicot K, Desramé J, Botsen D, El Hajbi F, Gonzalez D, Lepage C, Bouché O,
et al. Safety of FOLFIRI + Durvalumab +/− Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59. Biomedicines. 2022; 10(5):1211.
https://doi.org/10.3390/biomedicines10051211
Chicago/Turabian Style
Evrard, Camille, Thomas Aparicio, Emilie Soularue, Karine Le Malicot, Jérôme Desramé, Damien Botsen, Farid El Hajbi, Daniel Gonzalez, Come Lepage, Olivier Bouché,
and et al. 2022. "Safety of FOLFIRI + Durvalumab +/− Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59" Biomedicines 10, no. 5: 1211.
https://doi.org/10.3390/biomedicines10051211
APA Style
Evrard, C., Aparicio, T., Soularue, E., Le Malicot, K., Desramé, J., Botsen, D., El Hajbi, F., Gonzalez, D., Lepage, C., Bouché, O., Tougeron, D., & on behalf of the DURIGAST—PRODIGE 59 Investigators/Collaborators.
(2022). Safety of FOLFIRI + Durvalumab +/− Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59. Biomedicines, 10(5), 1211.
https://doi.org/10.3390/biomedicines10051211
